[CAS NO. 332348-12-6] Abatacept

Ships within

Stock

Price

Qty

Total

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-108829
Brand:	MCE
CAS:	332348-12-6

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Abatacept]

For research use only. We do not sell to patients.

Summary

Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) ^[1] . Abatacept is a selective T-cell co-stimulation modulator and a protein drug for the autoimmune diseases ^[2] .

In Vivo

Abatacept reduces paw edema, and the SC Multiple-dose group shows significantly greater (t _obs = 2.50) paw edema reduction compared with the IV dose group ^[2] .
Abatacept exhibits linear PK across the studied doses. The NCA clearance (CL) is 20.8 mL/day/kg, volume (V _ss ) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7% ^[2] .
Abatacept (oral; 10 mg/kg; every 2 days) reduces the proportion of activated T cells (CD44highCD62L–) and inhibits the up-regulation of ICOS and CD71 in homozygous DO11.10 RAG-2 ^–/– BALB/c (H-2d/d) mice ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Lewis rats (6-9 weeks old) with weights of 150-175 g ^[2]
Dosage:	10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29
Administration:	IV or SC
Result:	Reduced paw edema, and the SC Multiple-dose group showed significantly greater (t _obs = 2.50) paw edema reduction compared with the IV dose group.

Animal Model:	Male Lewis rats (6-9 weeks old) with weights of 150-175 g ^[2]
Dosage:	10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29 (Pharmacokinetic Study)
Administration:	IV or SC
Result:	The NCA clearance (CL) is 20.8 mL/day/kg, volume (V _ss ) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00409838	Bristol-Myers Squibb	Rheumatoid Arthritis	April 2007	Phase 3
NCT00277225	Bristol-Myers Squibb	Psoriasis Vulgaris	November 1995	Phase 1
NCT01315938	Karolinska Institutet\|Institute of Rheumatology, Prague\|King´s College Hospital NHS Trust	Polymyositis\|Dermatomyositis	January 2011	Phase 2
NCT01299961	University of California, Los Angeles	Rheumatoid Arthritis	March 2011	Phase 3
NCT04610476	University of Erlangen-Nürnberg Medical School	Psoriatic Arthritis\|Withdrawal\|Reduction	October 19, 2020	Phase 3
NCT03882008	University of Washington\|Bristol-Myers Squibb	Rheumatoid Arthritis	May 23, 2019	Phase 4
NCT00886795	Johns Hopkins University\|Bristol-Myers Squibb	Urticaria	May 2009	Phase 1\|Phase 2
NCT01999868	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)	Psoriasis	March 19, 2014	Phase 2
NCT01773707	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|Juvenile Diabetes Research Foundation	Abnormal Glucose Tolerance\|Type 1 Diabetes	March 2013	Phase 2
NCT02652273	NHS Greater Glasgow and Clyde\|University of Glasgow	Arthritis, Rheumatoid	January 2016	Phase 4
NCT04872218	Philippe Bégin\|Centre hospitalier de l´Université de Montréal (CHUM)\|St. Justine´s Hospital	Peanut Allergy	March 1, 2022	Phase 2
NCT01890473	Bristol-Myers Squibb	Rheumatoid Arthritis	July 2013	Phase 1
NCT01743131	Boston Children´s Hospital\|FDA Office of Orphan Products Development	Graft vs Host Disease\|Malignancy	February 2013	Phase 2
NCT04255134	St George´s, University of London	Rheumatoid Arthritis	September 7, 2020	Phase 4
NCT01439204	Bristol-Myers Squibb	Rheumatoid Arthritis	October 2011	Phase 1
NCT01758198	Bristol-Myers Squibb\|Ono Pharmaceutical Co. Ltd	Rheumatoid Arthritis	April 11, 2013	Phase 4
NCT02353780	Dr. Larry W. Moreland\|Genentech, Inc.\|Bristol-Myers Squibb\|University of Pittsburgh	Rheumatoid Arthritis (RA)	March 2015	Phase 4
NCT01860976	Bristol-Myers Squibb	Psoriatic Arthritis	June 17, 2013	Phase 3
NCT02078882	Christopher Bowlus, MD\|Bristol-Myers Squibb\|University of California, Davis	Primary Biliary Cirrhosis	September 2014	Phase 4
NCT00430677	Bristol-Myers Squibb	Systemic Lupus Erythematosus	June 2007	Phase 2\|Phase 3
NCT00442611	Stanford University\|Bristol-Myers Squibb	Scleroderma, Diffuse\|Scleroderma, Systemic	November 2008	Phase 1\|Phase 2
NCT00048581	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2002	Phase 3
NCT00162279	Bristol-Myers Squibb	Rheumatoid Arthritis	October 2000	Phase 2
NCT03619876	Columbia University\|Bristol-Myers Squibb	Rheumatoid Arthritis\|Myocardial Inflammation	July 10, 2019	Phase 4
NCT02722694	Jiangsu Simcere Pharmaceutical Co., Ltd.\|Bristol-Myers Squibb	Rheumatoid Arthritis (RA)	August 2016	Phase 3
NCT00279760	Bristol-Myers Squibb	Rheumatoid Arthritis		Phase 1\|Phase 2
NCT01917058	Columbia University	Alopecia Areata	August 2013	Phase 2
NCT04106804	University of Erlangen-Nürnberg Medical School	Evaluate Bone Changes in Patients With PsA	June 6, 2018	Phase 4
NCT02557100	Bristol-Myers Squibb	Rheumatoid Arthritis	November 19, 2015	Phase 4
NCT02592798	Bristol-Myers Squibb	Nephrotic Syndrome\|Focal Segmental Glomerulosclerosis\|Minimal Change Disease	March 9, 2016	Phase 2
NCT05080218	Jeffrey Curtis\|University of Alabama at Birmingham\|University of Nebraska\|University of Pennsylvania\|AbbVie\|Bristol-Myers Squibb\|Novartis\|Eli Lilly and Company\|Pfizer\|Foundation for Advancing Science Technology Education and Research	Rheumatoid Arthritis\|Psoriatic Arthritis\|Spondylarthritis	November 15, 2021	Phase 4
NCT00534313	Bristol-Myers Squibb	Psoriatic Arthritis	November 2007	Phase 2
NCT03669861	Massachusetts General Hospital\|Bristol-Myers Squibb	IgG4-related Disease	November 13, 2018	Phase 2
NCT04449224	Hanyang University\|Ministry of Health, Republic of Korea	Rheumatoid Arthritis	April 27, 2020
NCT02840175	Assistance Publique - Hôpitaux de Paris	Juvenile Idiopathic Arthritis	May 18, 2017	Phase 3
NCT04572620	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Interstitial Lymphocytic Lung Disease	September 7, 2020
NCT01279954	Oregon Health and Science University\|Bristol-Myers Squibb	Uveitis	January 2012	Phase 2
NCT01001832	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2009	Phase 2\|Phase 3
NCT01351480	Arthritis & Rheumatic Disease Specialties Research\|Bristol-Myers Squibb	Rheumatoid Arthritis	June 2011	Phase 3
NCT04871191	Assistance Publique - Hôpitaux de Paris\|URC-CIC Paris Descartes Necker Cochin	Granulomatosis With Polyangiitis\|Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis	October 2022	Phase 2
NCT05335928	Massachusetts General Hospital\|Bristol-Myers Squibb	Myocarditis Acute\|Cancer	June 22, 2022	Phase 3
NCT04946669	The First Affiliated Hospital with Nanjing Medical University\|National Natural Science Foundation of China	Dermatomyositis\|Abatacept	February 1, 2021	Early Phase 1
NCT03059888	Johns Hopkins University\|Bristol-Myers Squibb	Myasthenia Gravis	April 12, 2017	Early Phase 1
NCT00124449	Bristol-Myers Squibb	Arthritis, Rheumatoid	February 2005	Phase 2
NCT00306878	Bristol-Myers Squibb	Psoriasis Vulgaris	August 1995	Phase 1
NCT01693640	NYU Langone Health\|Bristol-Myers Squibb	Female Patients With Behcet´s Syndrome	June 2012	Early Phase 1
NCT01173120	Bristol-Myers Squibb	Rheumatoid Arthritis (RA)	November 2009	Phase 3
NCT02281058	Brigham and Women´s Hospital\|Bristol-Myers Squibb	Vitiligo	January 2015	Phase 1
NCT03457142	Roswell Park Cancer Institute\|Bristol-Myers Squibb	Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	September 11, 2018	Phase 2
NCT04120831	University of Erlangen-Nürnberg Medical School	Rheumatoid Arthritis	October 7, 2019	Phase 2
NCT01954979	Beth Israel Deaconess Medical Center\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	Chronic Graft Versus Host Disease	October 2013	Phase 1
NCT03414502	University of Nebraska	Rheumatoid Arthritis	August 2007	Phase 3
NCT01116427	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)	Multiple Sclerosis, Relapsing-Remitting	September 2010	Phase 2
NCT02867800	Monica Bhatia\|Columbia University	Sickle Cell Disease\|Graft Versus Host Disease	July 2016	Phase 1
NCT04377867	Marmara University\|The Scientific and Technological Research Council of Turkey	LRBA Deficiency\|CTLA4 Haploinsufficiency	January 15, 2020
NCT04203875	Stuart Knechtle, M.D.\|Duke University	Autoimmune Hepatitis	March 9, 2020	Phase 1
NCT00345748	Bristol-Myers Squibb	Rheumatoid Arthritis	June 2006	Phase 2
NCT00162201	Bristol-Myers Squibb	Rheumatoid Arthritis	October 2003	Phase 1
NCT03215927	Rohit Aggarwal, MD\|Bristol-Myers Squibb\|University of Pittsburgh	Myositis\|Interstitial Lung Disease	June 1, 2017	Phase 2
NCT05428488	University Hospital, Montpellier	Rheumatoid Arthritis	September 2022	Phase 3
NCT01844518	Bristol-Myers Squibb	Active Polyarticular Juvenile Idiopathic Arthritis	August 30, 2013	Phase 3
NCT01142726	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2010	Phase 3
NCT02915159	Bristol-Myers Squibb	Sjogrens Disease	December 6, 2016	Phase 3
NCT02805010	Jiangsu Simcere Pharmaceutical Co., Ltd.\|Bristol-Myers Squibb	Rheumatoid Arthritis (RA)	October 2016	Phase 1
NCT04474847	University of Pennsylvania	Giant Cell Arteritis	March 15, 2021	Phase 3
NCT01272856	Benaroya Research Institute\|Bristol-Myers Squibb	Relapsing Polychondritis	January 2011	Phase 1
NCT01846975	Rüdiger B. Müller\|Bristol-Myers Squibb\|Cantonal Hospital of St. Gallen	Rheumatoid Arthritis	May 2013	Phase 4
NCT03632187	University Hospital, Brest\|Bristol-Myers Squibb	Polymyalgia Rheumatica	December 13, 2018	Phase 3
NCT02270957	Oklahoma Medical Research Foundation\|Bristol-Myers Squibb	Systemic Lupus Erythematosus	January 2014	Phase 2
NCT05195645	Assistance Publique - Hôpitaux de Paris	Myocarditis	October 4, 2022	Phase 2
NCT05289167	NYU Langone Health	Graft-versus-host Disease	March 13, 2022	Phase 1\|Phase 2
NCT05426252	The Hospital for Sick Children\|Thalassemia Foundation of Canada	Thalassemia in Children	March 22, 2022	Phase 1\|Phase 2
NCT03841357	Duke University	Juvenile Idiopathic Arthritis	October 29, 2019	Phase 3
NCT00533897	Bristol-Myers Squibb	Rheumatoid Arthritis	November 2007	Phase 3
NCT04529902	Brigham and Women´s Hospital\|National Institute on Aging (NIA)\|Rutgers University\|Johns Hopkins University	Rheumatoid Arthritis	August 17, 2020
NCT00559585	Bristol-Myers Squibb	Rheumatoid Arthritis (RA)	January 2008	Phase 3
NCT04186871	Bristol-Myers Squibb	Autoimmune Disorder\|Rheumatoid Arthritis\|Systemic Lupus Erythematosus\|Primary Sjögren´s Syndrome	January 7, 2020	Phase 2
NCT01917708	Emory University	Hurler Syndrome\|Fanconi Anemia\|Glanzmann Thrombasthenia\|Wiskott-Aldrich Syndrome\|Chronic Granulomatous Disease\|Severe Congenital Neutropenia\|Leukocyte Adhesion Deficiency\|Shwachman-Diamond Syndrome\|Diamond-Blackfan Anemia\|Dyskeratosis-congenita\|Chediak-Higashi Syndrome\|Severe Aplastic Anemia\|Thalassemia Major\|Hemophagocytic Lymphohistiocytosis\|Sickle Cell Disease	January 2014	Phase 1
NCT03192969	Bristol-Myers Squibb	Giant Cell Arteritis	July 15, 2017	Phase 3
NCT05621759	NYU Langone Health	Graft Vs Host Disease	August 23, 2022	Phase 2
NCT03680092	Dimitrios Tzachanis, MD PhD\|Bristol-Myers Squibb\|University of California, San Diego	GVHD\|Hematologic Neoplasms	November 26, 2019	Phase 2
NCT05451615	Zhejiang Provincial People´s Hospital	Abatacept\|Treatment Compliance\|Rheumatoid Arthritis	September 30, 2022	Phase 3
NCT00663702	Bristol-Myers Squibb	Arthritis, Rheumatoid	May 2008	Phase 3
NCT01350804	Novartis Pharmaceuticals\|Novartis	Rheumatoid Arthritis	September 2011	Phase 3
NCT03669367	Fundacion Clinic per a la Recerca Biomédica	Palindromic Rheumatism, Wrist	April 1, 2019	Phase 4
NCT04529863	Brigham and Women´s Hospital\|National Institute on Aging (NIA)\|Rutgers University\|Johns Hopkins University	Rheumatoid Arthritis	August 17, 2020
NCT04118153	Carla Greenbaum, MD\|Juvenile Diabetes Research Foundation\|Medical College of Wisconsin\|Benaroya Research Institute	Type 1 Diabetes	March 5, 2021	Early Phase 1
NCT01314495	Julian M. Mackay-Wiggan\|Columbia University	Alopecia Totalis+Universalis	September 2011	Phase 2
NCT02053727	University of California, Los Angeles	Rheumatoid Arthritis\|Chronic Hepatitis B	July 2014	Not Applicable
NCT00406653	Bristol-Myers Squibb	Crohn´s Disease	December 2006	Phase 3
NCT02232880	Vanderbilt University Medical Center\|Bristol-Myers Squibb	Hypertension	August 2014	Phase 2
NCT02598466	Bristol-Myers Squibb\|Hexor, South Africa	Rheumatoid Arthritis	July 2015
NCT00122382	Bristol-Myers Squibb	Rheumatoid Arthritis	July 2005	Phase 3
NCT00277199	Bristol-Myers Squibb	Healthy Subjects	September 2002	Phase 1
NCT00705367	Bristol-Myers Squibb	Lupus Nephritis	August 2008	Phase 1
NCT03737708	Astellas Pharma Korea, Inc.\|Astellas Pharma Inc	Rheumatoid Arthritis (RA)	February 13, 2019	Phase 4
NCT02027298	The Cleveland Clinic\|Bristol-Myers Squibb	Primary Sjogren´s Syndrome\|Secondary Sjogren´s Syndrome\|Inflammatory Arthritis\|Rheumatoid Arthritis	November 2013	Phase 2
NCT00119678	Bristol-Myers Squibb	Systemic Lupus Erythematosus	September 2005	Phase 2
NCT04686929	The First Affiliated Hospital of Soochow University	Abatacept\|Acute-graft-versus-host Disease\|Haplo-identical HCT\|Prevention	June 1, 2021	Phase 1\|Phase 2
NCT00558506	Charite University, Berlin, Germany\|Bristol-Myers Squibb	Ankylosing Spondylitis	January 2008	Phase 2
NCT02778906	University of Erlangen-Nürnberg Medical School\|Bristol-Myers Squibb	Arthralgia\|Arthritis	November 2014	Phase 3
NCT04909801	Bristol-Myers Squibb	Rheumatoid Arthritis	September 15, 2021	Phase 3
NCT00989235	Bristol-Myers Squibb	Rheumatoid Arthritis	April 2007	Phase 3
NCT02971683	Bristol-Myers Squibb	Polymyositis\|Dermatomyositis\|Autoimmune Necrotizing Myopathy\|Overlap Myositis\|Juvenile Myositis Above the Age of 18	May 4, 2017	Phase 3
NCT02594735	George Washington University	Dermatomyositis	November 2015	Phase 4
NCT04472494	Bristol-Myers Squibb	COVID-19\|SARS-CoV-2	October 14, 2020	Phase 2
NCT04529876	Brigham and Women´s Hospital\|National Institute on Aging (NIA)\|Rutgers University\|Johns Hopkins University	Rheumatoid Arthritis	August 17, 2020
NCT01295151	Julia Brown\|University of Leeds	Rheumatoid Arthritis	August 2011	Phase 4
NCT04955366	Emory University	Renal Transplant Recipient	September 22, 2021	Phase 2
NCT00162266	Bristol-Myers Squibb	Rheumatoid Arthritis	October 2000	Phase 2
NCT02108860	University of South Florida\|The Cleveland Clinic\|Bristol-Myers Squibb\|University of Pennsylvania\|National Institutes of Health (NIH)\|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Granulomatosis With Polyangiitis (Wegener´s)\|Granulomatosis With Polyangiitis\|Wegener´s Granulomatosis\|ANCA-Associated Vasculitis	April 25, 2015	Phase 3
NCT00124982	Bristol-Myers Squibb	Rheumatoid Arthritis	April 2005	Phase 3
NCT03784261	Shinshu University	Rheumatoid Arthritis	December 17, 2018	Phase 2
NCT04380740	Boston Children´s Hospital\|Bristol-Myers Squibb	Graft Vs Host Disease	March 30, 2022	Phase 2
NCT00276250	Emory University\|Juvenile Diabetes Research Foundation	Type 1 Diabetes Mellitus	December 2005	Phase 2
NCT03929601	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Institutes of Health (NIH)\|Juvenile Diabetes Research Foundation	Type 1 Diabetes Mellitus	February 17, 2020	Phase 2
NCT05303272	Tongji Hospital\|Wuhan Central Hospital\|Wuhan Hospital of Traditional Chinese Medicine	Pemphigus Vulgaris	February 1, 2021	Phase 4
NCT00048932	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2002	Phase 3
NCT00739960	University of Chicago\|Bristol-Myers Squibb	Sarcoidosis	August 2008	Phase 2
NCT02067910	University Medical Center Groningen\|Bristol-Myers Squibb	Sjögren´s Syndrome	August 2014	Phase 3
NCT00767325	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2008	Phase 3
NCT03924401	Emory University\|Thrasher Research Fund\|Sickle Cell Transplant Advocacy & Research Alliance (STAR)\|Aflac Cancer and Blood Disorders Center\|Bristol-Myers Squibb	Graft Versus Host Disease	August 22, 2019	Phase 2
NCT00095147	Bristol-Myers Squibb	Rheumatoid Arthritis	February 2005	Phase 3
NCT02169544	Bristol-Myers Squibb	Rheumatoid Arthritis	January 31, 2014
NCT01221636	Bristol-Myers Squibb	Rheumatoid Arthritis	October 2010	Phase 1
NCT02429934	University of California, Los Angeles\|Bristol-Myers Squibb	Systemic Lupus Erythematosus Arthritis	October 2015	Phase 1\|Phase 2
NCT01339481	Astellas Pharma Inc\|Perseid Therapeutics LLC	Rheumatoid Arthritis	February 2011
NCT00929864	Bristol-Myers Squibb	Rheumatoid Arthritis	October 2009	Phase 3
NCT00279734	Bristol-Myers Squibb	Rheumatoid Arthritis	August 2004	Phase 1
NCT02018042	Columbia University\|Bristol-Myers Squibb	Alopecia Areata	September 2013	Phase 2
NCT00547521	Bristol-Myers Squibb	Rheumatoid Arthritis (RA)	December 2007	Phase 3
NCT00482066	Imperial College London\|Bristol-Myers Squibb	ANCA-associated Vasculitis	November 2007	Phase 2
NCT02547493	University Hospital, Montpellier\|Bristol-Myers Squibb	Rheumatoid Arthritis	March 3, 2016	Not Applicable
NCT03492658	Leiden University Medical Center	Rheumatoid Arthritis\|Rheumatic Diseases	May 17, 2018	Phase 4
NCT01333878	Orrin M Troum, M.D. and Medical Associates\|Bristol-Myers Squibb	Rheumatoid Arthritis	March 2011	Phase 2\|Phase 3
NCT00420199	Bristol-Myers Squibb	Active Rheumatoid Arthritis	May 2007	Phase 3
NCT04477642	Beth Israel Deaconess Medical Center\|Boston Children´s Hospital\|Bristol-Myers Squibb\|Brigham and Women´s Hospital	COVID-19	August 2020	Phase 1\|Phase 2
NCT00774852	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)	Lupus Nephritis\|Lupus Erythematosus, Systemic	November 2008	Phase 2
NCT00287547	Bristol-Myers Squibb	Psoriasis Vulgaris	March 1997	Phase 2
NCT02161406	Dinesh Khanna, MD, MS\|Bristol-Myers Squibb\|National Institute of Allergy and Infectious Diseases (NIAID)\|University of Michigan	Diffuse Cutaneous Systemic Sclerosis	September 2014	Phase 2
NCT00410410	Bristol-Myers Squibb	Ulcerative Colitis	December 2006	Phase 3
NCT00556439	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)\|The Cleveland Clinic\|Office of Rare Diseases (ORD)\|Rare Diseases Clinical Research Network	Takayasu´s Arteritis\|Giant Cell Arteritis	December 2008	Phase 2
NCT00468208	University of Pennsylvania\|Office of Rare Diseases (ORD)\|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)\|Rare Diseases Clinical Research Network	Wegener´s Granulomatosis	February 2008	Phase 1\|Phase 2
NCT05170672	Bristol-Myers Squibb
NCT02037737	Bristol-Myers Squibb	Rheumatoid Arthritis	September 30, 2016
NCT00254293	Bristol-Myers Squibb	Rheumatoid Arthritis	January 2006	Phase 1\|Phase 2
NCT03652961	NYU Langone Health\|Dartmouth-Hitchcock Medical Center\|Bristol-Myers Squibb	Rheumatoid Arthritis	June 2, 2019	Phase 4
NCT00048568	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2002	Phase 3
NCT00035529	Bristol-Myers Squibb	Multiple Sclerosis	November 2001	Phase 2
NCT02109666	Bristol-Myers Squibb	Rheumatoid Arthritis	March 2008
NCT01012492	Boston Children´s Hospital	AML\|ALL\|Undifferentiated Leukemia\|Biphenotypic Leukemia\|Refractory Anemia\|Refractory Anemia With Ringed Sideroblasts\|Refractory Cytopenia With Multilineage Dysplasia\|Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts\|Refractory Anemia With Excess Blasts-1 (5-10% Blasts)\|Refractory Anemia With Excess Blasts-2 (10-20% Blasts)\|Myelodysplastic Syndrome, Unclassified\|MDS Associated With Isolated Del (5q)	November 2009	Phase 2
NCT01844895	Bristol-Myers Squibb	Rheumatoid Arthritis	April 2013	Phase 3
NCT04344873	University of Utah\|National Institute on Aging (NIA)	Cardiovascular Diseases\|Inflammation\|Aging	November 30, 2022	Early Phase 1
NCT01555879	Arthritis Northwest PLLC\|Bristol-Myers Squibb	Arthritis, Rheumatoid	March 2012
NCT04925375	Children´s Hospital Medical Center, Cincinnati\|Bristol-Myers Squibb	Interstitial Lung Disease\|Common Variable Immunodeficiency	July 14, 2021	Phase 2
NCT01714817	Bristol-Myers Squibb	Lupus Nephritis	January 22, 2013	Phase 3
NCT04593940	Daniel Benjamin\|National Center for Advancing Translational Sciences (NCATS)\|Biomedical Advanced Research and Development Authority\|Duke University	Covid19	October 15, 2020	Phase 3
NCT00484289	Bristol-Myers Squibb	Rheumatoid Arthritis	December 2006	Phase 3
NCT03733067	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	CTLA4 Haploinsufficency\|Chronic Cytopenia	November 28, 2022	Phase 1\|Phase 2
NCT00095173	Bristol-Myers Squibb	Juvenile Rheumatoid Arthritis	December 2003	Phase 3
NCT03086343	AbbVie	Rheumatoid Arthritis (RA)	May 9, 2017	Phase 3
NCT03084419	Cambridge University Hospitals NHS Foundation Trust\|Bristol-Myers Squibb	Rheumatoid Arthritis\|Interstitial Lung Disease	June 26, 2018	Phase 2
NCT01835470	Bristol-Myers Squibb\|Ono Pharmaceutical Co. Ltd	Juvenile Idiopathic Arthritis	August 9, 2013	Phase 3
NCT00784459	Washington University School of Medicine\|Bristol-Myers Squibb	Atopic Asthma	October 2008	Phase 2
NCT03440892	Vastra Gotaland Region	Rheumatoid Arthritis	November 1, 2017
NCT03871361	Universitaire Ziekenhuizen KU Leuven\|Ziekenhuis Netwerk Antwerpen (ZNA)	Eye Diseases\|Uveitis	April 1, 2019	Phase 2
NCT03227419	Lille Catholic University	Arthritis, Rheumatoid	January 22, 2018	Phase 4
NCT03714022	Bristol-Myers Squibb	Rheumatoid Arthritis	November 9, 2018	Phase 1
NCT01557374	Assistance Publique - Hôpitaux de Paris\|Ministry of Health, France	Rheumatoid Arthritis	April 2012	Phase 4
NCT02504268	Bristol-Myers Squibb	Rheumatoid Arthritis	September 3, 2015	Phase 3

Appearance

Solid

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Kiykim A, et al. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. J Allergy Clin Immunol Pract. 2019 Jun 22.
[2] Lon HK, et al. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):701-12.
[3] Patakas A, et al. Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells. Arthritis Rheumatol. 2016 Mar;68(3):627-38.

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart